Protagonist Therapeutics

Protagonist Therapeutics is a peptide-therapeutic platform company that has translated its proprietary peptide-design technology into two late-stage commercial assets through major-pharma partnerships, without commercialising independently. FY2025 revenue USD 74 M is entirely collaboration-revenue noise (milestone recognition from Takeda and Johnson & Johnson) rather than commercial sales. Reported net loss of USD 1.81 per share and -154.9% profit margin are misleading for a clinical-stage biotech where cash burn is funded by upfront and milestone proceeds. The economics that matter are the peak-sales potential of the two partnered assets and the percentage of profit Protagonist retains.

The 2026 strategic story has two threads. First, Rusfertide (PTG-300): an injectable mimetic of the natural hormone hepcidin, partnered with Takeda for global commercialisation but with Protagonist retaining a 50% US profit share. The VERIFY Phase 3 pivotal trial in polycythemia vera (PV) read out positive in 2024 and was confirmed in 2025 — 76% of treated patients met the primary endpoint (no phlebotomy needed weeks 20-32) versus 33% placebo. BLA filing is expected H1 2026 with FDA approval H2 2026 / early 2027. PV is a 160,000-patient US prevalence with current standard of care being phlebotomy plus cytoreductive therapy (hydroxyurea, interferon). Rusfertide peak sales potential is USD 1.5-2.0 bn globally. Second, Icotrokinra (JNJ-2113, ex-PN-235): an oral peptide IL-23 receptor antagonist, fully partnered with J&J in 2022 for USD 50 M upfront + tiered royalties. J&J reported positive Phase 3 ICONIC results in moderate-to-severe plaque psoriasis in 2025 and is on track for 2026 launch — Icotrokinra is the first oral IL-23 pathway agent and competes against Bristol-Myers Sotyktu (deucravacitinib, TYK2 inhibitor) in oral-systemic psoriasis. Psoriasis peak sales USD 3-5 bn globally; Protagonist royalty in mid-single-digit range.

The 2026 question is whether Rusfertide FDA approval clears in 2026, whether the platform can demonstrate a third peptide candidate in clinic by 2027, and whether the Icotrokinra J&J launch trajectory in psoriasis validates the oral-IL-23 differentiation thesis.

Top holders Q1/2026: Baker Bros Advisors 9.5% (specialist biotech investor, position since 2018), Vanguard 8.4%, BlackRock 6.1%, RA Capital Management 5.2%, State Street 3.4%, Janus Henderson 2.8%, Avoro Capital 2.4%. Free-float effectively 90% with no founder-block — both co-founders Dinesh Patel (CEO) and Lawrence Steinman are below 1% individual ownership.

Most interesting move: RA Capital added 28% to its position in Q4/2025 — sustained accumulation by one of biotech's most credible specialist funds, consistent with Rusfertide approval-trajectory conviction. Baker Bros has been a top-3 holder since 2018 and trimmed only 5% during the 2024 peak — uncommon discipline among biotech long-term holders. Janus Henderson opened a fresh 2.8% position in Q1/2026 at USD 95-105 prices, a value-pivot from generalist healthcare into a near-approval asset.

Insider activity: CEO Dinesh Patel (co-founder, in role since 2007) made no open-market purchases in 2024-2025 — usual restraint pattern. CFO Asif Ali bought USD 280k of stock in November 2025 at USD 92 — first major insider purchase since the 2018 secondary offering. CMO Sam Saks (joined 2022 from Genentech) exercised options in Q4/2025 and held 90% of resulting shares. Lawrence Steinman has not transacted since 2020.

Short interest 13.6% (short ratio 10.7 days to cover) — elevated. The bear thesis is concentrated on Rusfertide commercial uptake risk (existing PV standard-of-care is well-established, Jakafi/Vonjo are launched), Icotrokinra competitive intensity against Sotyktu and TYK2 follow-on programs, and the platform-extension risk (Protagonist has not advanced a third asset to Phase 2 yet). A successful Rusfertide approval combined with J&J Icotrokinra launch would be the textbook biotech-platform validation event.

EV/Revenue 84x is meaningless given collaboration-revenue noise. The right framework is sum-of-parts NPV. Rusfertide US profit share NPV (assuming 75% approval probability, USD 1.5 bn peak sales, 50% Protagonist share) approximately USD 2.0-2.5 bn. Icotrokinra royalty NPV (assuming 6% effective royalty on USD 3 bn peak J&J sales) approximately USD 1.2-1.8 bn. Platform optionality (third + fourth peptide programs at risk-adjusted NPV) USD 0.8-1.2 bn. Total NPV USD 4.0-5.5 bn versus enterprise value approximately USD 6.2 bn — implying valuation already prices most success scenarios. Sell-side PT consensus USD 116.75 (range USD 100-137): Cantor Fitzgerald most bullish at USD 137 (Rusfertide approves + Icotrokinra peaks above USD 3 bn + platform third asset emerges), Stifel most bearish at USD 100 (Rusfertide modest uptake + Icotrokinra USD 1.5 bn peak). 12 analysts cover, recommendation strong-buy. Implied probability of clean Rusfertide approval + Icotrokinra USD 2+ bn peak in current price approximately 75%. Bull case USD 150 (+47%) on Rusfertide approves H2 2026 + Icotrokinra above USD 3 bn + platform PN-881 advances. Bear case USD 60 (-41%) on Rusfertide CRL or delay + Icotrokinra below USD 1.5 bn peak.

1. H1 2026: Rusfertide BLA submission — confirms approval trajectory
2. H2 2026: Icotrokinra Johnson & Johnson commercial launch in moderate-to-severe plaque psoriasis
3. Late 2026 / Q1 2027: Rusfertide FDA PDUFA decision — first commercial Protagonist asset

Protagonist Therapeutics is the cleanest peptide-platform validation story in late-stage biotech. The thesis is two near-term commercial assets via major-pharma partnerships, leaving Protagonist with platform optionality without commercial-build dilution. At enterprise value USD 6.2 bn versus my sum-of-parts NPV USD 4-5.5 bn, the stock is fairly priced for the base case and would need either Rusfertide commercial uptake to surprise or platform third-asset to emerge for material upside. I size PTGX at 0.75-1.5% as a high-conviction biotech satellite. The trade I would not make is sizing above 2.0% — Rusfertide approval is highly probable but PV is a competitive indication and commercial uptake risk is real. Add trigger: Rusfertide FDA approval + Icotrokinra first-six-month sales above USD 100 M. Cut trigger: Rusfertide CRL or any J&J commercial setback for Icotrokinra in 2026. This is a near-approval-event trade, not a hold-forever name — when Rusfertide is approved and the catalyst is realised, the multiple needs to compress to reflect commercial-execution risk.